Solasia Pharma KK (4597) Price & Analysis

Compare

1 Followers

4597 Stock Chart & Stats

¥27.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥27.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥27.00 - ¥48.00

Previous CloseN/A

Volume8.51M

Average Volume (3M)41.98M

Market Cap

¥9.01B

Enterprise Value¥6.93B

Total Cash (Recent Filing)¥1.39B

Total Debt (Recent Filing)¥159.00M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding273,414,370

10 Day Avg. Volume52,616,870

30 Day Avg. Volume41,982,023

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)3.93

Price to Sales (P/S)16.06

P/FCF Ratio-8.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2

Revenue Forecast (FY)¥1.92B

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthLow leverage and a sizable equity base provide structural financial flexibility, allowing the company to sustain operations and fund R&D or trials without immediate refinancing. This cushion reduces bankruptcy risk and supports multi‑quarter execution despite operating losses.

Revenue Rebound And Growth TrendA strong revenue rebound signals improving commercial traction and market acceptance of products or partnerships. Sustained top‑line recovery over several quarters enhances prospects for operating leverage and makes a path to profitability more attainable if cost structure is controlled.

Improving Cash Burn DirectionTrend improvement in free cash flow shows progress in narrowing cash burn, indicating management is beginning to moderate expenditures or scale revenues. Continued improvement reduces near‑term financing needs and increases odds of reaching positive cash generation within several quarters.

Bears Say

Persistent UnprofitabilityDeep and persistent net and operating losses mean the business lacks sustainable profitability at current scale. Over time, continued losses will erode equity and force dilution or costly financing, limiting strategic flexibility and making long‑term viability contingent on material margin improvement.

Negative Cash GenerationConsistent negative operating and free cash flow necessitate ongoing external funding or asset draws. This structural cash shortfall raises execution risk: future development, commercialization, or trials require capital, pressuring management to raise funds at potentially dilutive terms.

Margin PressureA sharp decline in gross margin suggests worsening product economics or mix shifts that could compress future profitability. If margins don't recover, revenue growth alone may be insufficient to cover fixed costs, prolonging losses and weakening the path to sustainable operating leverage.

Solasia Pharma KK News

Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs

Solasia Pharma KK ( ($JP:4597) ) has provided an update. Solasia Pharma has provided an update on its...

21d ago

Solasia Pharma Narrows Losses on Higher Sales but Withholds 2026 Outlook

Solasia Pharma KK ( ($JP:4597) ) just unveiled an update. Solasia Pharma reported a 35.4% year-on-year increase in...

21d ago

Solasia Pharma Advances Oncology Pipeline and Expands Global Reach for Key Cancer Drugs

Solasia Pharma KK ( ($JP:4597) ) has provided an update. Solasia Pharma has updated investors on the status...

21d ago

Solasia Pharma Narrows Losses as Sales Rise but Withholds 2026 Forecast

The latest announcement is out from Solasia Pharma KK ( ($JP:4597) ). Solasia Pharma reported a 35.4% year-on-year...

21d ago

Solasia Grants MAAB Exclusive China Rights to Sancuso in Sales Framework Overhaul

Solasia Pharma KK ( ($JP:4597) ) has provided an announcement. Solasia Pharma has signed a license agreement granting...

1M ago

Solasia Pharma Cuts FY2025 Sales Outlook on China Delays and License Changes

The latest announcement is out from Solasia Pharma KK ( ($JP:4597) ). Solasia Pharma has revised downward its...

2M ago

Solasia Pharma Expands Global Reach with Strategic Partnerships

Solasia Pharma KK ( ($JP:4597) ) just unveiled an announcement. Solasia Pharma K.K. has announced its consolidated financial...

4M ago

Solasia Pharma Reports Nine-Month Financial Results with Sales Growth Amidst Challenges

Solasia Pharma KK ( ($JP:4597) ) has provided an update. Solasia Pharma K.K. reported its consolidated financial results...

4M ago

Solasia Pharma Reports Q2 Financials and Pipeline Progress

Solasia Pharma KK ( ($JP:4597) ) has issued an update. Solasia Pharma K.K. announced its consolidated financial results...

7M ago

Solasia Pharma Reports First Half 2025 Financial Results Amid Ongoing Challenges

Solasia Pharma KK ( ($JP:4597) ) has issued an announcement. Solasia Pharma K.K. reported its consolidated financial results...

7M ago

4597 FAQ

What was Solasia Pharma KK’s price range in the past 12 months?

Solasia Pharma KK lowest stock price was ¥27.00 and its highest was ¥48.00 in the past 12 months.

What is Solasia Pharma KK’s market cap?

Solasia Pharma KK’s market cap is ¥9.01B.

When is Solasia Pharma KK’s upcoming earnings report date?

Solasia Pharma KK’s upcoming earnings report date is May 20, 2026 which is in 75 days.

How were Solasia Pharma KK’s earnings last quarter?

Solasia Pharma KK released its earnings results on Feb 13, 2026. The company reported -¥0.53 earnings per share for the quarter, missing the consensus estimate of N/A by -¥0.53.

Is Solasia Pharma KK overvalued?

According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Solasia Pharma KK pay dividends?

Solasia Pharma KK does not currently pay dividends.

What is Solasia Pharma KK’s EPS estimate?

Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Solasia Pharma KK have?

Solasia Pharma KK has 273,414,370 shares outstanding.

What happened to Solasia Pharma KK’s price movement after its last earnings report?

Solasia Pharma KK reported an EPS of -¥0.53 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.226%.

Which hedge fund is a major shareholder of Solasia Pharma KK?

Currently, no hedge funds are holding shares in JP:4597

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Solasia Pharma KK

Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.